A Randomised Controlled Trial on the Efficacy of Ketamine versus Electroconvulsive Therapy in Severe Depression with Suicidal Ideation
Neuropsychobiology · 05.02.2026 · 85 (3) · 156-167
DOI: 10.1159/000550863 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neuropsychobiology, online erschienen am 05.02.2026. Verfasst von Lavanya Seth und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, IMS and SUM Hospital, Bhubaneswar, India. Hauptthemen laut MEDLINE: Ketamine, Electroconvulsive Therapy, Suicidal Ideation, Major Depressive Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Depression
Abstract (Originalsprache)
Introduction
Severe depressive episodes with suicidal ideation present major therapeutic challenges and often require interventions beyond standard antidepressant therapy. Electroconvulsive therapy (ECT) remains a cornerstone treatment for refractory depression, while ketamine, an N-methyl-D-aspartate receptor antagonist, has emerged as a rapid-acting antidepressant with potential benefits in reducing suicidal ideation. This study compares the efficacy, onset of action, and tolerability of intravenous ketamine and ECT as adjunctive treatments in severe major depressive disorder with active suicidal ideation.
Methods
A randomised controlled trial was conducted at a tertiary care psychiatry department in India, enrolling 64 patients aged 18–60 years with severe depression (HAM-D ≥19, SSI ≥4). Participants were randomly assigned to receive either intravenous ketamine (n = 31) or ECT (n = 33), alongside ongoing oral antidepressants. Both groups underwent six treatment sessions over 2 weeks. Outcomes were assessed at baseline, post-treatment, and 4 weeks after completion. Primary endpoints included changes in depression severity (HAM-D) and suicidal ideation (SSI), while secondary outcomes included response and remission rates, as well as safety and tolerability profiles.
Results
Both ECT and ketamine significantly reduced depressive symptoms and suicidal ideation (p < 0.001). HAM-D scores declined from 27 to 1 in the ECT group and from 26 to 2 in the ketamine group by the 4-week follow-up. SSI scores showed parallel improvement, from 12.1 to 1.2 with ECT and 12.6 to 2.0 with ketamine. Ketamine demonstrated a faster onset of clinical improvement, while ECT showed slightly greater durability of response. Side effects were mild in both groups, though ECT was associated with transient cognitive impairment, whereas ketamine produced minor dissociative and urinary symptoms.
Conclusion
Ketamine offers a faster reduction in suicidal ideation than ECT, making it a promising acute intervention. Both are effective, safe adjunctive therapies, with treatment choice guided by patient profile and tolerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, IMS and SUM Hospital, Bhubaneswar, India.
- Department of Psychiatry, IMS and SUM Hospital, Bhubaneswar, India, drjbiswal@gmail.com.
Zitieren
APA
Seth, L., Biswal, J., Sahoo, S., Shetty, R., & Das, J. (2026). A Randomised Controlled Trial on the Efficacy of Ketamine versus Electroconvulsive Therapy in Severe Depression with Suicidal Ideation. Neuropsychobiology, 85(3), 156-167. https://doi.org/10.1159/000550863
Vancouver
Seth L, Biswal J, Sahoo S, Shetty R, Das J. A Randomised Controlled Trial on the Efficacy of Ketamine versus Electroconvulsive Therapy in Severe Depression with Suicidal Ideation. Neuropsychobiology. 2026;85(3):156-167. doi:10.1159/000550863
BibTeX
@article{Seth2026,
author = {Seth, Lavanya and Biswal, Jitendriya and Sahoo, Surjeet and Shetty, Riya and Das, Jamuna},
title = {A Randomised Controlled Trial on the Efficacy of Ketamine versus Electroconvulsive Therapy in Severe Depression with Suicidal Ideation},
journal = {Neuropsychobiology},
year = {2026},
volume = {85},
number = {3},
pages = {156--167},
doi = {10.1159/000550863}
}
EUVIMED